By a News Reporter-Staff News Editor at Biotech Week -- Researchers detail new data in Drugs and Therapies. According to news originating from Seoul, South Korea, by NewsRx correspondents, research stated, "Docetaxel is a potent anticancer drug, but development of an oral formulation has been hindered mainly due to its poor oral bioavailability. In this study, solid lipid nanoparticles (SLNs) surface-modified by Tween 80 or D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS 1000) were prepared and evaluated in terms of their feasibility as oral delivery systems for docetaxel."
Our news journalists obtained a quote from the research from Seoul National University, "Tween 80-emulsified and TPGS 1000-emulsified tristearin-based lipidic nanoparticles were prepared by a solvent-diffusion method, and their particle size distribution, zeta potential, drug loading, and particle morphology were characterized. An in vitro release study showed a sustained-release profile of docetaxel from the SLNs compared with an intravenous docetaxel formulation (Taxotere ®). Tween 80-emulsified SLNs showed enhanced intestinal absorption, lymphatic uptake, and relative oral bioavailability of docetaxel compared with Taxotere in rats. These results may be attributable to the absorption-enhancing effects of the tristearin nanoparticle. Moreover, compared with Tween 80-emulsified SLNs, the intestinal absorption and relative oral bioavailability of docetaxel in rats were further improved in TPGS 1000-emulsified SLNs, probably due to better inhibition of drug efflux by TPGS 1000, along with intestinal lymphatic uptake."
According to the news editors, the research concluded: "Taken together, it is worth noting that these surface-modified SLNs may serve as efficient oral delivery systems for docetaxel."
For more information on this research see: Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake. International Journal of Nanomedicine, 2014;9():495-504. International Journal of Nanomedicine can be contacted at: Dove Medical Press Ltd, PO Box 300-008, Albany, Auckland 0752, New Zealand (see also Drugs and Therapies).
The news correspondents report that additional information may be obtained from H.J. Cho, Seoul National University, Inst Pharmaceut Sci, Coll Pharm & Res, Seoul 151742, South Korea. Additional authors for this research include J.W. Park, I.S. Yoon and D.D. Kim.
Keywords for this news article include: Asia, Antineoplastics, Pharmaceuticals, Seoul, Docetaxel, South Korea, Nanoparticle, Nanotechnology, Mitotic Inhibitors, Drugs and Therapies, Emerging Technologies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC